Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)

The global phase 3 IMpower010 study evaluated adjuvant atezolizumab versus best supportive care (BSC) following platinum‐based chemotherapy in patients with resected stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report a subgroup analysis in patients enrolled in Japan. Eligible patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenmotsu, Hirotsugu, Sugawara, Shunichi, Watanabe, Yasutaka, Saito, Haruhiro, Okada, Morihito, Chen‐Yoshikawa, Toyofumi Fengshi, Ohe, Yuichiro, Nishio, Wataru, Nakagawa, Shizuka, Nagao, Haruka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746048/
https://www.ncbi.nlm.nih.gov/pubmed/36062851
http://dx.doi.org/10.1111/cas.15564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746048/
https://www.ncbi.nlm.nih.gov/pubmed/36062851
http://dx.doi.org/10.1111/cas.15564

Ejemplares similares